MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced management will participate in the following investor conferences.
CARMEL, Ind., May 08, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced management will participate in the following investor conferences.
JMP Securities Life Sciences Conference:
| Date: | Monday, May 15th, 2023 | |
| Format: | Corporate Presentation by Kent Hawryluk, President and CEO, and 1x1 Investor Meetings | |
| Time: | 1:00 PM ET | |
| Location: | New York, NY |
Piper Sandler Spring Biopharma Symposium:
| Date: | Wednesday, May 17th, 2023 | |
| Format: | 1x1 Investor Meetings | |
| Location: | Boston, MA |
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. The Company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
ian.stone@evokegroup.com
619-849-5388
Investor Inquiries:
Irina Koffler
LifeSci Advisors
ikoffler@lifesciadvisors.com
917-734-7387
